Interesting RDNT Put And Call Options For February 2026

RadNet (RDNT) option setups present income-oriented opportunities: a $65 put trading at a $2.55 bid implies a net effective purchase price of $62.45 versus the current share price of $72.75 (put ~11% out-of-the-money) with a 68% chance to expire worthless and a 3.92% cash-return (22.73% annualized) if it does. On the call side, a $75 strike covered call fetches $3.90, representing an 8.45% total return if called at Feb 2026 (strike ~3% above spot), a 56% chance to expire worthless, and a 5.36% premium boost (31.06% annualized); implied vols are ~55% (put) and 54% (call) versus a 12-month realized volatility of 43%.

Analysis

Market structure: The option market is signalling asymmetric risk/reward on RDNT (stock $72.75): 11%‑OTM $65 puts trade at $2.55 (cost basis $62.45) with a 68% OTM probability, while $75 calls yield $3.90 with a 56% OTM probability into Feb 2026 (~~1.5 months). Winners are option sellers and buy‑and‑hold investors seeking yield; losers are naked upside speculators and liquidity takers if assignment creates forced buying/selling around strike levels. The $65 strike functions as a temporary psychological and liquidity floor and will attract buy interest if put sellers are assigned.

Risk assessment: Tail risks include regulatory/reimbursement shocks (Medicare policy changes), operational setbacks (clinic closures/litigation) or a broad small‑cap selloff that pushes RDNT < $60 (material assignment/capital strain). Near term (days–2 months) primary risk is volatility/assignment and IV crush; medium term (quarters) is earnings/reimbursement clarity; long term depends on market share and consolidation in imaging. Hidden dependency: implied vol (54–55%) exceeds realized (43%), so sellers are being paid for skew but are exposed to event jumps; IV spikes will quickly widen loss potential.

Trade implications: Direct: for investors wanting stock, sell Feb 2026 RDNT $65 puts to acquire at $62.45 — limit allocation to 1–3% portfolio and size so max assignment ≤5% equity. Conservative alternative: buy/write at $72.75 and sell $75 Feb 2026 calls to collect $3.90 (8.45% return to expiration). Options strategy: prefer defined‑risk credit spreads (sell $65/$60 put spread) rather than naked puts to cap tail losses.

Contrarian angles: Consensus treats this as a simple yield pick but underrates event risk — if a regulatory or earnings surprise occurs IV will spike and short sellers will be hurt. Given IV is ~25% rich to realized, disciplined volatility sellers can earn attractive annualized yield (20–30% annualized) but must manage assignment and set hard stop‑loss thresholds (e.g., close if RDNT < $60 or IV > 70%). Historical parallel: small‑cap healthcare name mean reversion after policy clarity, but outcomes vary; size and defined risk are crucial.

Key Decisions for Investors

• Establish a 1–3% portfolio position in RDNT via selling Feb 2026 $65 puts at $2.55 (effective basis $62.45). Size position so worst‑case assignment ≤5% of equity; close or roll if RDNT trades below $60 or IV spikes >70%.
• If already long RDNT at ~$72.75, implement a buy‑write: sell Feb 2026 $75 calls at $3.90 to generate ~8.45% to expiration; if RDNT > $80 by Jan 15, buy back calls and re‑deploy into higher strikes to avoid forced sale.
• Prefer defined‑risk spreads over naked exposure: sell the $65/$60 Feb 2026 put spread instead of naked puts to cap downside (max loss $5 less premium). Allocate no more than 2% portfolio to net short‑vol trades in this name.
• Set monitored triggers: exit/hedge positions if (a) RDNT < $60, (b) IV rises above 70% or gap up/down >15% on news, or (c) company issues adverse reimbursement guidance; reassess after the next quarterly report (~within 60–90 days).